Federal Label Approval as Potential Litigation Shield: What Monsanto v. Durnell Means for Regulated Manufacturers

On June 25, 2026, the U.S. Supreme Court handed regulated manufacturers a significant litigation win. In Monsanto Co. v. Durnell, a 7-2 majority held that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts state-law failure-to-warn claims where those claims would require a label warning beyond what EPA has approved. The decision has implications that reach well beyond pesticides — and manufacturers of pharmaceuticals, medical devices, and other federally regulated products should pay close attention.

What the Court Decided

John Durnell sued Monsanto in Missouri state court, claiming that two decades of Roundup use caused his non-Hodgkin's lymphoma and that Monsanto should have included a cancer warning on the product's label. EPA had registered Roundup without requiring a cancer warning — a conclusion the agency has maintained since 1991 and reaffirmed on multiple occasions despite challenges from international health bodies. A Missouri jury found for Durnell and awarded him $1.25million dollars.

The U.S. Supreme Court reversed and found that FIFRA's preemption clause bars any state requirement for pesticide labeling that is "in addition to or different from" federal requirements. The Court held that EPA's registration process — which requires the agency to affirmatively approve a pesticide's label and to determine that the label contains all warnings necessary to protect health — constitutes a binding federal requirement. Once EPA approves a label, a manufacturer is legally required to use it. A state tort verdict that demands a different or additional warning necessarily conflicts with that federal mandate and is preempted.

Why Riegel v. Medtronic Is Central to This Decision

The Court grounded its analysis heavily in Riegel v. Medtronic, the 2008 decision that established broad preemption for state-law claims targeting FDA-approved Class III medical devices. The majority in Durnell was explicit: FIFRA's preemption clause is "materially identical" to the Medical Device Amendments' preemption clause, and the two statutes operate the same way. Just as FDA's premarket approval process imposes specific device-level requirements that displace state tort standards, EPA's registration and label approval process imposes specific product-level requirements that do the same.

For medical device manufacturers, this is significant reinforcement of the Riegel preemption decision. Durnell reaffirms that Riegel's preemption framework is not an artifact of device-specific statutory language — it reflects a broader congressional judgment, expressed across multiple regulatory schemes, that uniform federal label determinations should not be second-guessed by juries. The Court also signaled that this logic extends to other federal statutes with similar preemption language, expressly listing provisions governing meat, poultry, eggs, cosmetics, OTC drugs, and certain food labeling requirements.

What This Means for Pharma, Device, and Chemical Manufacturers

Several practical consequences flow from this decision. First, where a federal agency has affirmatively reviewed and approved a product's label — including its warnings — a state failure-to-warn claim demanding something more is preempted. The specificity of the agency's determination matters: a general statutory misbranding standard is not enough, according to the Court in Durnell. What counts is whether the agency made a product-specific labeling judgment.

Durnell also flatly rejected the argument that state tort law parallels FIFRA merely because both require "adequate" warnings. That framing, the Court said, operates at too high a level of generality and would effectively nullify FIFRA's preemption clause. Manufacturers facing similar arguments under the FDCA's misbranding provisions should press this point aggressively.

The preemption defense applies even when new safety information emerges post-approval. The Court acknowledged that new data could prompt EPA to revise a label — but held that the theoretical possibility of future agency action does not strip the existing approval of its preemptive force. The appropriate remedy for new safety concerns is a petition to the agency, not a state tort suit.

Finally, parallel claims did not survive. The dissent argued that Durnell's claim merely paralleled FIFRA's misbranding prohibition and should therefore be allowed to proceed. The majority disagreed. EPA's product-specific registration determination — not the general statutory standard — is the relevant federal requirement, and a state claim that imposes anything beyond it is preempted.

Important Caveats

Durnell is a FIFRA decision, and its direct holding applies to pesticide labeling. Extension to pharmaceutical, device, and other regulated product contexts will require statute-specific analysis. The strength of the preemption defense will turn on whether the relevant agency affirmatively approves label content — as FDA does in the premarket approval process and, to a more limited extent, in the NDA and ANDA processes. Contexts where agency review is less comprehensive or where labeling authority is shared will present harder questions that will turn on the particular regulations and agency review for the label approval. Medical device manufacturers relying on Riegel are on the firmest ground; pharmaceutical and OTC manufacturers will need to assess their approval records carefully.

The Takeaway for Manufacturers and Their Counsel